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Abstract 
 
Objectives 
This study aims to highlight the benefits of Bayesian mixed treatment comparison (MTC), 
within a case study of the efficacy of three treatments (pegfilgrastim, filgrastim and 
lenograstim) for the prevention of febrile neutropenia (FN) following chemotherapy. 
 
Methods 
Two published meta-analyses have assessed the relative efficacy of the three treatments based 
on head-to-head trials. In the present study, all the trials from these meta-analyses were 
synthesised within a single network in a Bayesian MTC. Following a systematic review, the 
evidence base was then updated to include further recently-published trials. The meta-
analyses and MTC were re-analysed using the updated evidence base. 
 
Results 
Using data from the previously-published meta-analyses only, the relative risk of FN for 
pegfilgrastim vs. no treatment was estimated at 0.08 (95% confidence interval: 0.03, 0.18) 
from the head-to-head trial and 0.27 (95% credible interval: 0.12, 0.60) from the MTC, 
reflecting strong inconsistency between the results of the direct and indirect methodologies. 
When subsequently-published head-to-head trials were included, the meta-analysis estimate 
increased to 0.29 (95% confidence interval: 0.15, 0.55), while the MTC gave a relative risk of 
0.34 (95% credible interval: 0.23, 0.54). The initial MTC results were therefore a better 
predictor of subsequent study results than was the direct trial. The MTC was also able to 
estimate the probability that there were clinically significant difference in efficacy between 
the treatments. 
 
Conclusions 
Bayesian MTC provides clinically relevant information, including a measure of the 
consistency of direct and indirect evidence. Where inconsistency exists, it should not always 
be assumed that the direct evidence is more appropriate. 
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Introduction 
 
There is often a need to synthesise evidence from multiple studies when evaluating medical 
interventions from a clinical or health policy perspective. Meta-analysis is an established 
statistical method for this synthesis when the evidence consists of several head-to-head 
comparisons of two treatments. However, there are often more than two treatments that could 
be used in a given situation. Even when a head-to-head choice is being made, the two 
interventions may have been compared with further treatments as well as, or instead of, each 
other. The ability of standard meta-analysis to synthesise evidence on more than two 
treatments is limited.  
 
The estimation of the relative effectiveness of two treatments for which no head-to-head 
evidence is available is known as an indirect comparison. Bayesian methods provide a 
coherent framework for indirect comparisons, due to their explicit representation of 
parameter uncertainty.  Where there are head-to-head comparisons in addition to the direct 
evidence, then the method can be extended to synthesise both direct and indirect evidence 
and produce an estimate of effectiveness that draws on the complete evidence base (1). This 
is known as a mixed treatment comparison (MTC).  
 
The benefit of indirect comparisons is clear where no head-to-head trials exist. However, the 
value of going beyond the direct evidence with a mixed treatment comparison is more 
controversial. It is our experience that clinicians and decision-makers are often sceptical of 
the value of indirect evidence when direct evidence is available. This is reflected in the 
current methods guide for technology appraisal issued by the National Institute for Health 
and Clinical Excellence, which states that ‘the Institute has a preference for data from head-
to-head RCTs’ (2). 
 
Our view is that the synthesis of direct and indirect evidence has the potential to provide 
useful information alongside the head-to-head comparison. To illustrate this potential, as well 
as demonstrate additional benefits from the Bayesian indirect comparison methodology, we 
carried out a synthesis of the evidence around granulocyte colony-stimulating factors (G-
CSFs) for prevention of febrile neutropenia (FN) during chemotherapy. Three G-CSFs are 
currently in use: filgrastim, pegfilgrastim, and lenograstim. The evidence synthesis aimed to 
inform economic modelling of the most cost-effective of these treatments for prevention of 
FN.  
 
 
Methods  
 
 
In order to populate the economic model with efficacy evidence, we carried out a systematic 
review of the literature. Two systematic reviews and meta-analyses of G-CSFs in relation to 
reducing FN events were identified. Kuderer et al(3) analysed studies of primary G-CSF 
prophylaxis (pegfilgrastim, filgrastim or lenograstim) versus no primary prophylaxis, whilst 
Pinto et al(4) analysed studies of prophylaxis with pegfilgrastim versus filgrastim. We 
assumed that these two systematic reviews comprehensively identified the relevant literature 
for the period covered by their search strategy. No head-to-head studies had been identified 
by the published systematic reviews comparing lenograstim with the other two G-CSFs, and 
only one head-to-head trial had been found of pegfilgrastim vs. no primary G-CSF (5). The 
magnitude of the effect recorded in this trial appeared inconsistent with expectations given 
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the results from meta-analyses of pegfilgrastim vs. filgrastim and filgrastim vs. no primary G-
CSF. In order to quantify the extent of this apparent inconsistency, and to provide indirect 
estimates of the efficacy of lenograstim relative to the other two G-CSFs, we carried out an 
MTC of the evidence base as identified by Kuderer and Pinto.  
 
In addition to the systematic reviews, our search of the literature identified three further 
studies of pegfilgrastim vs. no primary G-CSF(5-8) that had been published subsequently 
(incorporating four comparisons, since one of the studies assessed two populations). This 
provided an additional source of evidence to test whether the direct evidence alone, or the 
synthesis of evidence provided by the MTC, proved a more accurate prediction of the results 
of future head-to-head trials. To assess this, we carried out a conventional random-effects 
meta-analysis of the complete direct evidence base (including the additional studies) for the 
comparison of pegfilgrastim vs. no primary G-CSF. We also carried out another MTC on the 
entire evidence base, to assess the impact of the additional evidence.  
 
In our view, one of the benefits of Bayesian methods in evidence synthesis is the ability to 
characterise uncertainty around parameters in terms of a posterior density function. This 
allows for statements to be made about the information present in an evidence base that go 
beyond whether a null hypothesis can be rejected at an arbitrary level of significance, to give 
instead results that are easier to interpret clinically. A commonly presented example is the 
credible interval, defined so that there is a 5% chance (for a 95% credible interval) that the 
true value lies outside the range. Conventional confidence intervals are often wrongly 
interpreted this way, illustrating the greater intuitive appeal of the credible interval (9).  
 
In fact, the posterior density can be used to calculate the probability that the true value lies 
within any given range. If the range is defined as less than one, and the outcome measure is 
undesirable, this gives the probability that the treatment is superior to the control (avoiding 
the need to specify an arbitrary significance level). For equivalence comparisons, a range 
could be identified to represent clinical equivalence. For each of the pair-wise comparisons 
generated by the MTC, we calculated a 95% credible interval, the probability that treatment 
one was superior to treatment two, and the probability that the two treatments were 
equivalent. We defined equivalency for the sake of this case study as a relative risk of 1 +/- 
0.1. 
 
MTCs were carried out using the Bayesian modelling software WinBugs.(10). All posterior 
distributions were estimated using weakly informative prior distributions; gamma 
(0.001,0.001) distributions for precision parameters and normal (0,0.001) distributions for the 
logit of the probability of FN.  
 
 
Results 
 
 
The studies included in the analysis (those identified in the existing systematic reviews and 
the additional trials identified in our literature review) are described in Table 1, and the 
network of evidence is illustrated by Figure 1.  
 
Table 2 compares results from the MTC performed on the evidence base reported in the 
existing systematic reviews with the results from the meta-analyses they report. The results 
are reasonably consistent, with one exception – in the initial evidence base, there is a marked 
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difference between the direct and indirect estimates for the relative risk of FN with 
pegfilgrastim vs. placebo (0.08 vs. 0.27), such that each point estimate lies outside the 
confidence / credible interval of the other. Table 3 presents the updated MTC including the 
additional studies not identified in the existing systematic reviews, alongside a meta-analysis 
of the updated evidence base for pegfilgrastim versus no G-CSF. This demonstrates that, 
once this additional evidence is included, the direct and indirect estimates are reasonably 
consistent (0.29 vs. 0.34), and that the additional evidence has brought the head-to-head 
estimate in line with the MTC estimate, rather than the other way around. As shown in Table 
1, the MTC estimate from the original dataset was a better predictor of subsequent trial 
results than the head-to-head estimate. For the complete evidence base, the divergence 
between the direct and the synthesised evidence is greatest for the comparison of lenograstim 
with no G-CSF, although each estimate lies within the confidence / credible interval 
generated by its opposing method.  
 
The MTC uses Markov Chain Monte Carlo methods (11) to estimate the posterior 
distribution for each relative risk. Figure 2 illustrates this distribution for the FN relative risk 
for pegfilgrastim vs. lenograstim. From these distributions, estimates can be made of the 
comparative efficacy of lenograstim against the other two G-CSFs, despite the lack of direct 
evidence. The median relative risk of FN for pegfilgrastim vs. lenograstim is 0.71 and for 
lenograstim vs. filgrastim is 0.88. The posterior distributions can also be used to calculate the 
probability that one G-CSF is superior to another or that two G-CSFs are clinically equivalent 
(as defined in the methods) can be calculated.  Table 4 gives these results for the three 
pairwise comparisons of G-CSFs. The MTC showed that there is strong evidence for the 
superiority of pegfilgrastim over filgrastim; the probability that pegfilgrastim is superior is 
98%, and that the two drugs are clinically equivalent is 4%. The evidence that pegfilgrastim 
is superior to lenograstim is convincing, with an 86% probability of superiority and a 
probability of equivalence of 13%. The evidence that lenograstim is superior to filgrastim 
was less conclusive, with the comparative figures being 71% and 30%. 
 
Discussion 
 
The case study we present illustrates the argument that MTC provides a useful check of the 
consistency between the direct and indirect evidence. If inconsistency is found, we would 
caution against the automatic acceptance of the direct result. In our example, the MTC 
estimate proved the more accurate predictor of future head-to-head studies. If our economic 
modelling called for an estimate of the relative efficacy of each treatment against no G-CSF, 
and we had only the evidence from the two existing systematic reviews to draw on, then 
relying only on the head-to-head evidence would have provided us with a less accurate 
estimate of the efficacy of pegfilgrastim.  
 
It is true that, in this case study, there was only one head-to-head study in the initial evidence 
base for the relative efficacy of pegfilgrastim vs. placebo, and it is not unheard of for a single 
trial to prove to be an outlier, particularly if small. Whilst pointing out that the study was the 
largest single trial in the entire evidence base, we would agree that an MTC is most likely to 
be of value to decision-makers when head-to-head evidence is limited. However, we would 
argue that there may be value in carrying out an MTC even if several head-to-head studies 
exist, particularly in support of health economic evaluations. In most cases, we would expect 
the direct and indirect evidence to provide similar results; a reassuring additional finding. 
However, it is possible for such inconsistencies to arise with a larger head-to-head evidence 
base, and our view is that it is useful to identify such cases also. 
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Of course, if it is felt that the head-to-head estimate is always ‘more valid’ than the estimate 
from the complete evidence base, there is little to be gained by identifying discrepancies 
between the two.  In many situations, there will be clinical arguments for preferring the direct 
evidence. In this case study, for example, it could be argued that the baseline risk in the head-
to-head trials was lower than in the trials forming the indirect evidence base, and that this 
casts doubt on the indirect estimate. One benefit of identifying inconsistencies is that it 
encourages discussion of these issues. In response to the point raised above, it can be noted 
that the baseline risk and treatment effect relationship does not appear to apply within the 
head-to-head trials (as can be seen in table one). Furthermore, Kuderer et al point out that the 
evidence for such a relationship across the entire evidence base appears weak. Therefore, it 
does not seem that such a relationship can explain the particularly strong treatment effect 
recorded in the Vogel trial. In general, comparing the indirect and direct evidence can 
highlight when further investigation of factors driving heterogeneity is worthwhile, and (in a 
few cases), there may be an argument for placing some weight on the indirect evidence. For 
example, the patient populations in those trials may reflect the population of interest more 
closely than the head-to-head trial  
 
There are further benefits to Bayesian MTC. Bayesian analysis differs from the classical 
approach in that it models uncertainty around parameters. This technical difference allows it 
to provide clinically relevant information more easily. It is the reason why indirect 
comparisons can be made within a coherent framework. Results can be adapted without 
difficulty to the situation. The example we gave involving the probability of clinical 
equivalence shows how results can be presented that are clinically significant rather than 
statistically significant. It is particularly relevant to situations where treatments are thought a 
priori to be similar e.g. where drugs are of the same class, and have similar modes of action.  
 
 
 
Conclusions 
 
Bayesian evidence synthesis, carried out in addition to conventional meta-analysis, provides 
useful information for clinical and policy decision-making. This includes a measure of the 
consistency between direct and indirect evidence. The presence of inconsistency warrants 
further investigation. Whilst there are strong reasons for preferring direct evidence, it should 
not be assumed that the head-to-head estimate is always more appropriate.  
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Figure 1: Network of trials for mixed treatment comparison 
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Figure 2: Probability density function for posterior distribution of relative risk of 
febrile neutropenia under treatment with pegfilgrastim vs. lenograstim 
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Table 1: Incidence of febrile neutropenia (FN) in all studies of prophylactic G-CSFs 
 
Study Total N 
(arm 1) 
FN rate (%) Total N 
(arm 2) 
FN rate (%) p-value Relative risk of FN (95% 
confidence interval) 
 Primary pegfilgrastim No primary G-CSF   
Vogel 2005 463 6/463 (1.3%) 465 78/465  (17%) <0.001 0.08 (0.04-0.18) 
*Balducci 2007: solid tumour 343  (4%) 343  (10%) 0.001 0.40 (0.22-0.73) 
*Balducci 2007: NHL 73  (15%) 73  (37%) 0.004 0.41 (0.22-0.76) 
*Romieu 2007 (cycle 1 only) 30 4/30 (13%) 29 5/29  (17%)  0.77 (0.23-2.62) 
*von Minckwitz 2008 314 17/314 (5%) 253 55/253 (22%) <0.001 0.25 (0.15-0.43) 
 Primary filgrastim No primary G-CSF   
Doorduijn 2003 197 72/197 (37%) 192 86/192 (45%) NR 0.82 (0.64-1.04) 
Osby 2003 (CHOP) 101  (34%) 104  (50%) <0.001 0.68 (0.49-0.95) 
Osby 2003 (CNOP) 125  (32%) 125  (50%) <0.001 0.64 (0.47-0.87) 
Zinzani 1997 77 4/77 (5%) 72 15/72 (21%) 0.004 0.25 (0.09-0.73) 
Pettengell 1992 41 9/41 (22%) 39 17/39 (44%) 0.04 0.5 (0.25-0.98) 
Timmer-Bonte 2005 90 16/90 (18%) 85 27/85 (32%) 0.01 0.56 (0.33-0.96) 
Trillet-Lenoir 1993 65 17/65 (26%) 64 34/64 (53%) 0.002 0.49 (0.31-0.78) 
Crawford 1991 95  (40%) 104  (77%) <0.001 0.52 (0.4-0.68) 
Fossa 1998 129 25/129 (19%) 130 38/130 (29%) NR 0.66 (0.42-1.03) 
 Primary lenograstim No primary G-CSF   
Chevallier 1995 61 36/61 (59%) 59 42/59 (71%) NS 0.83 (0.64-1.08) 
Gisselbrecht 1997 82 52/82 (63%) 80 62/80 (78%) NS 0.82 (0.67-1.0) 
Bui 1995 (cycle 1) 22 5/22 (23%) 26 15/26 (58%) 0.02 0.39 (0.17-0.90) 
Gebbia 1994 23 5/23 (22%) 28 18/28 (64%) <0.001 0.34 (0.15-0.77) 
Gebbia 1993 43  (12%) 43  (33%) <0.05 0.36 (0.14-0.90) 
 Primary pegfilgrastim Primary filgrastim   
Green 2003 77 10/77 (13%) 75 15/75 (20%) NS 0.65 (0.31-1.35) 
Holmes 2002: phase III 149 14/149 (9%) 147 27/147 (18%) 0.029 0.51 (0.28-0.94) 
Holmes 2002: phase II 46 5/46 (11%) 25 2/25 (8%)# NS 1.36 (0.28-6.49) 
Grigg 2003 14 0/14 (0%) 13 1/13 (8%) NR N/A 
Vose 2003 (cycles 1 & 2) 29 6/29 (21%) 31 6/31 (19%) NS 1.07 (0.39-2.95) 
*Studies added as a result of updated search. 
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Table 2: Estimates of the comparative efficacy of FN treatments using head-to-head meta-analysis and MTC for the evidence base identified in the existing 
systematic reviews. 
 
  Pre-updated evidence base from existing systematic reviews 
 
Arm 1 Arm 2 No of 
studies 
No of 
patients 
a) Head-to-head meta-
analysis: relative risk of 
FN 
 (95% confidence 
interval), p-value 
b) Bayesian mixed 
treatment comparison: 
relative risk of FN 
(median, 95% credible 
interval) 
Pegfilgrastim No primary G-
CSF 
1 928 0.08 (0.04-0.18) 
p<0.001 
0.27 (0.12 – 0.60) 
Filgrastim No primary G-
CSF 
9 1835 0.61 (0.53 – 0.72), 
p<0.001(3) 
0.56 (0.41 - 0.68) 
Lenograstim No primary G-
CSF 
5 467 0.62 (0.44 – 0.88), 
p=0.007(3) 
0.51 (0.30 – 0.74) 
Pegfilgrastim Filgrastim 5 606 0.64 (0.43 – 0.97), 
p=0.033(4) 
0.49 (0.23 – 1.04) 
Pegfilgrastim Lenograstim 0 0 No direct trials 
 
0.53 (0.22 – 1.37) 
Lenograstim 
 
Filgrastim 0 0 No direct trials 0.93 (0.53 – 1.50) 
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Table 3 Estimates of the comparative efficacy of FN treatments using head-to-head meta-analysis and MTC for the entire evidence base. 
 
Treatment 1 Treatment 2 No of 
studies 
No of 
patients 
a) Head-to-head meta-
analysis: relative risk of 
FN  
 (95% confidence 
interval), p-value 
b) Bayesian MTC**: 
relative risk of FN 
(median, 95% credible 
interval) 
Pegfilgrastim No primary G-
CSF 
5* 2386 0.290 (0.150 – 0.550), 
p=0.002 
0.341 (0.226 – 0.535) 
Filgrastim No primary G-
CSF 
9 1835 0.614 (0.525 – 0.718), 
p<0.001(3) 
0.553 (0.433 – 0.671) 
Lenograstim No primary G-
CSF 
5 467 0.623 (0.442 – 0.879), 
p=0.007(3) 
0.486 (0.278 – 0.714) 
Pegfilgrastim Filgrastim 5 606 0.644 (0.430 – 0.965), 
p=0.033(4) 
0.619 (0.406 – 0.994) 
Pegfilgrastim Lenograstim 0 0 No direct trials 
 
0.710 (0.390 – 1.420) 
Lenograstim 
 
Filgrastim 0 0 No direct trials 0.879 (0.491 – 1.407) 
*There were 4 publications, but one trial(12) included two populations (lymphoma and solid tumour patients) which are analysed here separately, giving 5 comparisons in 
total. **MTC=mixed treatment comparison 
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Table 4: Estimates of the clinical and statistical comparability of G-CSFs 
 
Treatment 1 Treatment 2 Median Relative 
Risk of FN  
Probability that 
Treatment 1 is 
more efficacious 
than Treatment 2 
in preventing FN 
(RR > 1.0) 
Probability that 
Treatment 1 is 
clinically superior 
to Treatment 2 (RR 
> 1.1) 
Probability that 
Treatment 1 and 
Treatment 2 are 
clinically 
equivalent  
(0.9 < RR < 1.1) 
Probability that 
Treatment 1 is 
clinically inferior to 
Treatment 2 
(RR<0.9) 
Pegfilgrastim Filgrastim 0.619 98% 95% 4% 1% 
Pegfilgrastim Lenograstim 0.710 86% 79% 13% 8% 
Lenograstim Filgrastim 0.879 71% 54% 30% 16% 
 
 
 
